Omeros' narsoplimab stabilized kidney function and reduced urinary complement proteins in a patient with iga vasculitis

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in kidney disease was presented yesterday at the annual meeting of the american society of nephrology (asn). the work, conducted by a consortium from denmark and the united kingdom and led by peter garred, md, dmsc, chair and professor of clinical molecular medicine at the university of copenhagen, was d
OMER Ratings Summary
OMER Quant Ranking